MTOR and renal carcinoma: A patient with renal cancer who had failed two multi-targeted antiangiogenesis inhibitors and an mTOR inhibitor had a >80 % reduction in tumor burden after five cycles of carfilzomib and continued on therapy for 13 cycles until disease progression with a dural-based brain metastasis.